SCHEMBL28816407

SCHEMBL28816407

CC(C)(C)OC(=O)N1C(=O)CC[C@@H]1C(=O)NNC(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.44
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KLK7 P49862 3/20 0.42
SYK P43405 1/20 0.41
WNT3 P56703 1/20 0.41
SFRP1 Q8N474 1/20 0.41
FKBP1A P62942 1/20 0.40
PARP1 P09874 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
CTSL P07711 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
GSK3B P49841 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KLK5 Q9Y337 1/20 0.39
CPB1 P15086 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27996466 1.00 STS (0.44) STSHTTNPC1RAB9ASMN1; SMN2
SCHEMBL842288 0.86 KLK7 (0.49) KLK7FKBP1APARP1CTSL
SCHEMBL12890921 0.86 KLK7 (0.49) KLK7FKBP1APARP1CTSL
SCHEMBL1300740 0.86 KLK7 (0.49) KLK7FKBP1APARP1CTSL
SCHEMBL16611702 0.86 ALDH1A1 (0.44) NPC1RAB9ACTSLMEN1KMT2A
SCHEMBL14243945 0.83 ALDH1A1 (0.53) SMN1; SMN2KMT2A
SCHEMBL14243946 0.83 ALDH1A1 (0.53) SMN1; SMN2KMT2A
SCHEMBL3671572 0.82 SMN1; SMN2 (0.52) STSHTTNPC1RAB9ASMN1; SMN2
SCHEMBL3671569 0.82 SMN1; SMN2 (0.52) STSHTTNPC1RAB9ASMN1; SMN2
SCHEMBL9951077 0.81 KLK7 (0.47) NPC1RAB9ASMN1; SMN2KLK7FKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12103928-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2024-10-01 US disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
CN-106967066-B Novel ss-lactam enzyme inhibitor and preparation method thereof 明治制果药业株式会社 2019-07-30 CN disclosed
CN-105859609-B Beta-lactamase inhibitor and preparation method thereof 明治制果药业株式会社 2019-04-09 CN disclosed
CN-106967066-A New beta lactamase restrainer and preparation method thereof 明治制果药业株式会社 2017-07-21 CN disclosed
CN-104334559-B Beta-lactamase inhibitor and preparation method thereof 明治制果药业株式会社 2017-03-22 CN disclosed
CN-105859609-A Beta-lactamase inhibitor and process for preparing the same 明治制果药业株式会社 2016-08-17 CN disclosed
CN-104334559-A Novel beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO LTD 2015-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 STS 2920/4885HTT 2307/4885NPC1 903/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 STS 2920/4885HTT 2307/4885NPC1 903/4885
US-12103928-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 STS 2920/4885HTT 2307/4885NPC1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.